19-11007932-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_003072.5(SMARCA4):c.2032C>T(p.Gln678*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,474 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_003072.5 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMARCA4 | ENST00000646693.2 | c.2032C>T | p.Gln678* | stop_gained | Exon 14 of 36 | NM_001387283.1 | ENSP00000495368.1 | |||
SMARCA4 | ENST00000344626.10 | c.2032C>T | p.Gln678* | stop_gained | Exon 14 of 35 | 1 | NM_003072.5 | ENSP00000343896.4 | ||
SMARCA4 | ENST00000643549.1 | c.2032C>T | p.Gln678* | stop_gained | Exon 14 of 35 | ENSP00000493975.1 | ||||
SMARCA4 | ENST00000541122.6 | c.2032C>T | p.Gln678* | stop_gained | Exon 15 of 35 | 5 | ENSP00000445036.2 | |||
SMARCA4 | ENST00000643296.1 | c.2032C>T | p.Gln678* | stop_gained | Exon 14 of 34 | ENSP00000496635.1 | ||||
SMARCA4 | ENST00000644737.1 | c.2032C>T | p.Gln678* | stop_gained | Exon 14 of 34 | ENSP00000495548.1 | ||||
SMARCA4 | ENST00000589677.5 | c.2032C>T | p.Gln678* | stop_gained | Exon 15 of 35 | 5 | ENSP00000464778.1 | |||
SMARCA4 | ENST00000643995.1 | c.1444C>T | p.Gln482* | stop_gained | Exon 11 of 32 | ENSP00000496004.1 | ||||
SMARCA4 | ENST00000644963.1 | c.676C>T | p.Gln226* | stop_gained | Exon 7 of 28 | ENSP00000495599.1 | ||||
SMARCA4 | ENST00000644065.1 | c.757C>T | p.Gln253* | stop_gained | Exon 7 of 27 | ENSP00000493615.1 | ||||
SMARCA4 | ENST00000642350.1 | c.517C>T | p.Gln173* | stop_gained | Exon 6 of 27 | ENSP00000495355.1 | ||||
SMARCA4 | ENST00000643857.1 | c.385C>T | p.Gln129* | stop_gained | Exon 5 of 25 | ENSP00000494159.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461474Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 727056
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Rhabdoid tumor predisposition syndrome 2 Pathogenic:1
Loss-of-function variants in SMARCA4 are known to be pathogenic (PMID: 24658001, 24658002). This sequence change creates a premature translational stop signal (p.Gln678*) in the SMARCA4 gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in the germline of individuals with SMARCA4-related disease. ClinVar contains an entry for this variant (Variation ID: 486489). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.Q678* pathogenic mutation (also known as c.2032C>T), located in coding exon 13 of the SMARCA4 gene, results from a C to T substitution at nucleotide position 2032. This changes the amino acid from a glutamine to a stop codon within coding exon 13. This mutation has been reported in the homozygous state in an atypical teratoid/rhabdoid brain tumor biopsied from a 9-month old male; authors were unable to perform germline testing for the patient or the parents (Hasselblatt M et al. Am. J. Surg. Pathol., 2011 Jun;35:933-5). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at